| Robust meta-analytic-predictive priors in clinical trials with historical control information H Schmidli, S Gsteiger, S Roychoudhury, A O'Hagan, D Spiegelhalter, ... Biometrics 70 (4), 1023-1032, 2014 | 420 | 2014 |
| Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts F Bretz, H Schmidli, F König, A Racine, W Maurer Biometrical Journal: Journal of Mathematical Methods in Biosciences 48 (4 …, 2006 | 296 | 2006 |
| Advantages of Artificial Neural Networks (ANNs) as alternative modelling technique for data sets showing non-linear relationships using data from a galenical study on a solid … J Bourquin, H Schmidli, P van Hoogevest, H Leuenberger European Journal of Pharmaceutical Sciences 7 (1), 5-16, 1998 | 183 | 1998 |
| Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice‐daily capsules in Alzheimer's disease patients G Lefevre, G Sędek, SS Jhee, MT Leibowitz, HL Huang, A Enz, S Maton, ... Clinical Pharmacology & Therapeutics 83 (1), 106-114, 2008 | 163 | 2008 |
| Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12‐and 36‐month results G Levy, H Schmidli, J Punch, E Tuttle‐Newhall, D Mayer, P Neuhaus, ... Liver transplantation 12 (11), 1640-1648, 2006 | 160 | 2006 |
| Population pharmacokinetics of imatinib mesylate in patients with chronic‐phase chronic myeloid leukaemia: results of a phase III study H Schmidli, B Peng, GJ Riviere, R Capdeville, M Hensley, I Gathmann, ... British journal of clinical pharmacology 60 (1), 35-44, 2005 | 154 | 2005 |
| A faunistic approach to assess potential side-effects of genetically modified Bt-Corn on non-target arthropods under field conditions MP Candolfi, K Brown, C Grimm, B Reber, H Schmidli Biocontrol Science and Technology 14 (2), 129-170, 2004 | 140 | 2004 |
| Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations H Schmidli, F Bretz, A Racine, W Maurer Biometrical Journal 48 (4), 635-643, 2006 | 132 | 2006 |
| Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation JM Kovarik, H Tedesco, J Pascual, G Civati, MN Bizot, J Geissler, ... Therapeutic drug monitoring 26 (5), 499-505, 2004 | 121 | 2004 |
| Basic concepts of artificial neural networks (ANN) modeling in the application to pharmaceutical development J Bourquin, H Schmidli, P van Hoogevest, H Leuenberger Pharmaceutical development and technology 2 (2), 95-109, 1997 | 115 | 1997 |
| Comparison of artificial neural networks (ANN) with classical modelling techniques using different experimental designs and data from a galenical study on a solid dosage form J Bourquin, H Schmidli, P van Hoogevest, H Leuenberger European journal of pharmaceutical sciences 6 (4), 287-300, 1998 | 104 | 1998 |
| Beyond randomized clinical trials: use of external controls H Schmidli, DA Häring, M Thomas, A Cassidy, S Weber, F Bretz Clinical Pharmacology & Therapeutics 107 (4), 806-816, 2020 | 100 | 2020 |
| Application of artificial neural networks (ANN) in the development of solid dosage forms J Bourquin, H Schmidli, P van Hoogevest, H Leuenberger Pharmaceutical development and technology 2 (2), 111-121, 1997 | 100 | 1997 |
| Pharmacokinetics and electrocardiographic pharmacodynamics of artemether‐lumefantrine (Riamet®) with concomitant administration of ketoconazole in healthy … G Lefèvre, P Carpenter, C Souppart, H Schmidli, M McClean, D Stypinski British journal of clinical pharmacology 54 (5), 485-492, 2002 | 97 | 2002 |
| Rivastigmine exposure provided by a transdermal patch versus capsules F Mercier, G Lefèvre, HL Aaron Huang, H Schmidli, B Amzal, ... Current medical research and opinion 23 (12), 3199-3204, 2007 | 94 | 2007 |
| Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure–effect modeling RC Starling, JM Hare, P Hauptman, KR McCurry, HW Mayer, JM Kovarik, ... American journal of transplantation 4 (12), 2126-2131, 2004 | 93 | 2004 |
| On weakly informative prior distributions for the heterogeneity parameter in Bayesian random‐effects meta‐analysis C Röver, R Bender, S Dias, CH Schmid, H Schmidli, S Sturtz, S Weber, ... Research Synthesis Methods 12 (4), 448-474, 2021 | 86 | 2021 |
| Therapeutic drug monitoring for everolimus in kidney transplantation using 12‐month exposure, efficacy, and safety data MI Lorber, C Ponticelli, J Whelchel, HW Mayer, J Kovarik, Y Li, H Schmidli Clinical transplantation 19 (2), 145-152, 2005 | 85 | 2005 |
| The Effects of a Flexible Visual Acuity–Driven Ranibizumab Treatment Regimen in Age-Related Macular Degeneration: Outcomes of a Drug and Disease Model FG Holz, JF Korobelnik, P Lanzetta, P Mitchell, U Schmidt-Erfurth, S Wolf, ... Investigative Ophthalmology & Visual Science 51 (1), 405-412, 2010 | 84 | 2010 |
| Estimands and their role in clinical trials M Akacha, F Bretz, D Ohlssen, G Rosenkranz, H Schmidli Statistics in Biopharmaceutical Research 9 (3), 268-271, 2017 | 77 | 2017 |
